Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126074871 | 12607487 | 1 | I | 2015 | 20160115 | 20160729 | 20160729 | EXP | CA-ASTRAZENECA-2016SE05481 | ASTRAZENECA | 76.00 | YR | M | Y | 0.00000 | 20160729 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126074871 | 12607487 | 1 | PS | ZOLADEX LA | GOSERELIN ACETATE | 1 | Subcutaneous | 162 | MG | FL0056,HA0116 | 20578 | 10.8 | MG | IMPLANT |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126074871 | 12607487 | 1 | Prostate cancer metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126074871 | 12607487 | OT |
| 126074871 | 12607487 | LT |
| 126074871 | 12607487 | DE |
| 126074871 | 12607487 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126074871 | 12607487 | Cardiovascular disorder | |
| 126074871 | 12607487 | Death | |
| 126074871 | 12607487 | Malignant neoplasm progression | |
| 126074871 | 12607487 | Pain | |
| 126074871 | 12607487 | Respiratory disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126074871 | 12607487 | 1 | 20121022 | 0 |